Literature DB >> 18243785

Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women.

Eva A Operskalski1, Wendy J Mack, Howard D Strickler, Audrey L French, Michael Augenbraun, Phyllis C Tien, Maria C Villacres, LaShonda Y Spencer, Marina Degiacomo, Andrea Kovacs.   

Abstract

BACKGROUND: Co-infection with hepatitis C virus (HCV) is common among HIV-infected women.
OBJECTIVE: To further our understanding of the risk factors for HCV viremia and the predictors of HCV viral load among women. STUDY
DESIGN: We investigated sociodemographic, immunologic, and virologic factors associated with presence and level of HCV viremia among 1049 HCV-seropositive women, 882 of whom were HIV-infected and 167 HIV-uninfected at their entry into the Women's Interagency HIV Study.
RESULTS: Plasma HCV RNA was detected in 852 (81%) of these 1049 women (range: 1.2-7.8 log(10)copies/ml). HCV-viremic women were more likely to have an HIV RNA level >100,000 copies/ml (P=0.0004), to have reported smoking (P=0.01), or to be Black (P=0.005). They were less likely to have current or resolved hepatitis B infection. HCV RNA levels were higher in women who were >35 years old, or HIV-infected. Current smoking and history of drug use (crack/freebase cocaine, marijuana, amphetamines, or heroin) were each associated with both presence and level of viremia.
CONCLUSIONS: Substance abuse counseling aimed at eliminating ongoing use of illicit drugs and tobacco may reduce clinical progression, improve response to treatment, and decrease HCV transmission by lowering levels of HCV viremia in women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243785      PMCID: PMC3493623          DOI: 10.1016/j.jcv.2007.08.021

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  43 in total

1.  Suppression of human IL-1beta, IL-2, IFN-gamma, and TNF-alpha production by cigarette smoke extracts.

Authors:  Y Ouyang; N Virasch; P Hao; M T Aubrey; N Mukerjee; B E Bierer; B M Freed
Journal:  J Allergy Clin Immunol       Date:  2000-08       Impact factor: 10.793

2.  Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.

Authors:  D T Dieterich
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

3.  Cigarette smoking and hepatic lesions in patients with chronic hepatitis C.

Authors:  F Pessione; M J Ramond; C Njapoum; V Duchatelle; C Degott; S Erlinger; B Rueff; D C Valla; F Degos
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  Multicenter evaluation of hepatitis C RNA levels among female injection drug users.

Authors:  D L Thomas; J D Rich; P Schuman; D K Smith; J A Astemborski; K R Nolt; R S Klein
Journal:  J Infect Dis       Date:  2001-02-21       Impact factor: 5.226

5.  The natural history of hepatitis C virus infection: host, viral, and environmental factors.

Authors:  D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

6.  Relation between HIV-1 and hepatitis C viral load in patients with hemophilia.

Authors:  E S Daar; H Lynn; S Donfield; E Gomperts; M W Hilgartner; W K Hoots; D Chernoff; S Arkin; W Y Wong; C A Winkler
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

7.  Racial differences in HLA class II associations with hepatitis C virus outcomes.

Authors:  C L Thio; D L Thomas; J J Goedert; D Vlahov; K E Nelson; M W Hilgartner; S J O'Brien; P Karacki; D Marti; J Astemborski; M Carrington
Journal:  J Infect Dis       Date:  2001-05-30       Impact factor: 5.226

8.  Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers.

Authors:  A E Yeo; M Ghany; C Conry-Cantilena; J C Melpolder; D E Kleiner; J W Shih; J H Hoofnagle; H J Alter
Journal:  J Viral Hepat       Date:  2001-07       Impact factor: 3.728

9.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

10.  Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study.

Authors:  M Hisada; T R O'Brien; P S Rosenberg; J J Goedert
Journal:  J Infect Dis       Date:  2000-04-07       Impact factor: 5.226

View more
  23 in total

1.  Implications of hepatitis C viremia vs. antibody alone on transmission among male injecting drug users in three Afghan cities.

Authors:  Abdul Nasir; Catherine S Todd; Mohammad R Stanekzai; Christian T Bautista; Boulos A Botros; Paul T Scott; Jerome H Kim; Steffanie A Strathdee; Jeffrey Tjaden
Journal:  Int J Infect Dis       Date:  2010-12-28       Impact factor: 3.623

2.  Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

Authors:  S M Gadalla; L R Preiss; M E Eyster; J J Goedert
Journal:  J Viral Hepat       Date:  2011-03       Impact factor: 3.728

3.  Hepatitis C virus infection and biological false-positive syphilis tests.

Authors:  M Augenbraun; A French; M Glesby; L Sanchez-Keeland; M Young; R Greenblatt; A Sharma
Journal:  Sex Transm Infect       Date:  2010-04       Impact factor: 3.519

4.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

5.  Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users.

Authors:  Basmattee Boodram; Ronald C Hershow; Scott J Cotler; Lawrence J Ouellet
Journal:  Drug Alcohol Depend       Date:  2011-07-02       Impact factor: 4.492

6.  T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHS.

Authors:  Roksana Karim; Wendy J Mack; Naoko Kono; Phyllis C Tien; Kathryn Anastos; Jason Lazar; Mary Young; Seema Desai; Elizabeth T Golub; Robert C Kaplan; Howard N Hodis; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

7.  Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.

Authors:  April M Young; Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Dustin B Stephens; Jennifer R Havens
Journal:  J Med Virol       Date:  2012-09       Impact factor: 2.327

8.  Risk factors for stimulant use among homeless and unstably housed adult women.

Authors:  Elise D Riley; Martha Shumway; Kelly R Knight; David Guzman; Jennifer Cohen; Sheri D Weiser
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

9.  Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.

Authors:  Daryoush Behzadpour; Abbas Ahmadi Vasmehjani; Seyed Dawood Mousavi Nasab; Nayeb Ali Ahmadi; Rasoul Baharlou
Journal:  Pathog Glob Health       Date:  2016-11-10       Impact factor: 2.894

10.  Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS).

Authors:  Toni Frederick; Pamela Burian; Norah Terrault; Mardge Cohen; Michael Augenbraun; Mary Young; Eric Seaberg; Jessica Justman; Alexandra M Levine; Wendy J Mack; Andrea Kovacs
Journal:  AIDS Patient Care STDS       Date:  2009-11       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.